Real time prices by BATS. Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Cytodyn Inc. (CYDY) Nasdaq Listed. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Nasdaq 100. sell any security. It's packed with all of the company's key stats and salient decision making information. Stock analysis for CytoDyn Inc (CYDY:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Zacks Sector Rank Education - Learn more about the Zacks Sector Rank. Visit Performance Disclosure for information about the performance numbers displayed above. Average Target Price: NA: LT Growth Rate ... Research for CYDY ... stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices … CytoDyn stock forecast & analyst price target predictions based on a number of analysts offering 12-months price targets for CYDY in the last 3 months. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. To learn more, click here. CYDY Stock Buy Rating CytoDyn Inc Current Average Recommendation Strong Buy or Sell | Investors Hangout The average price target represents a 36.99% upside from the last price … Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for most of the leading investment web sties. One pot stock could skyrocket with looming interstate sales. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. You can opt out at any time. HC Wainwright has the highest price target set, predicting CYDY will reach $4.00 in the next twelve months. The company was formerly known as RexRay Corporation. A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CYDY, but not buy more shares or sell existing shares. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average 12-month stock price forecast for CytoDyn is 4.00, which is a decrease of -1.23% from the latest price. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. It is based on its current growth rate as well as the projected cash flow expected by the investors. The new super strain of hemp has 3X more CBD per bud than competitors’. The average analyst price target of CYDY is higher than 2.61% of stocks in the mid market cap category. * indicates the important links in the menu. To see all exchange delays and terms of use please see disclaimer. These returns cover a period from January 1, 1988 through January 4, 2021. The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. HC Wainwright has the lowest price target set, forecasting a price of $4.00 for CytoDyn in the next year. Fundamental company data provided by Zacks Investment Research. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. CYDY | Complete CytoDyn Inc. stock news by MarketWatch. CytoDyn is a biotechnology company focused on the clinical development and potential... Proactive leads the world in up-to-the-minute, multi-media … With medical cannabis sales expected to triple by 2026, investors still have massive opportunities if they find the right companies early. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. More Info. Add CYDY Price Alert Hide Sticky Hide Intro Moderator: Blane , JPG77 , Bulldog88 , justdafactss , Scooter McCabe , daemon57 Search This Board: 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 … Find the latest CYTODYN INC (CYDY) stock quote, history, news and other vital information to help you with your stock trading and investing. Their average twelve-month price target is $4.00, predicting that the stock has a possible downside of 1.23%. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. All rights reserved. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports. The scores are based on the trading styles of Value, Growth, and Momentum. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. CytoDyn Inc. (CYDY) Broker Recommendations. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports. PriceTargets.com keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. CytoDyn Inc. continues to be a target for short-sellers who continue to torpedo the bull thesis with weak ammunition and dreadful aim.Despite some critical hits, the bull juggernaut remains … The $38.40 average price target implies downside potential of 27%, but this could change should other analysts update their models to account for the recent share price appreciation. CYDY has … Summary. Find real-time CYDY - Cytodyn Inc stock quotes, company profile, news and forecasts from CNN Business. Their average twelve-month price target is $4.00, suggesting a possible upside of 86.9%. 1 brokerages have issued 12-month target prices for CytoDyn's stock. The Oregon grower has cracked the cannabis yield code. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. If you wish to go to ZacksTrade, click OK. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). View real-time stock prices and stock quotes for a full financial overview. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%. Other companies that are similar to CytoDyn include Blueprint Medicines, Turning Point Therapeutics, Perrigo, Galapagos, Atea Pharmaceuticals, Schrödinger, Biohaven Pharmaceutical, Emergent BioSolutions, Sage Therapeutics, Arena Pharmaceuticals, ACADIA Pharmaceuticals, PTC Therapeutics, Apellis Pharmaceuticals, Hutchison China MediTech and Reata Pharmaceuticals. Your … Zacks Sector Rank Education -- Learn more about the Zacks Sector Rank. That’s good news for people who can move now to become one of the company’s earliest investors. This Hold consensus rating has held steady for over two years. The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc) made by the brokerage firms for a given stock. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.93% per year. View today's stock price, news and analysis for CytoDyn Inc. (CYDY). A high-level overview of CytoDyn Inc. (CYDY) stock. CYDY -- USA Stock : USD 5.30 0.07 1.30% : Cytodyn's future stock price is the expected price of Cytodyn stock. View the latest price targets for CYDY. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. NASDAQ data is at least 15 minutes delayed. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation … CytoDyn Inc's variance in analysts' estimates is less than nearly 100% of all US stocks. The addition of a tycoon investor and a world renown cancer expert to the CYDY … A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Move your mouse over past months for details. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. © American Consumer News, LLC dba PriceTargets.com ® 2010-2021. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. On average, they anticipate CytoDyn's share price to reach $4.00 in the next twelve months. Visit www.zacksdata.com to get our data and content for your mobile app or website. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. CytoDyn's physical mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. Data is currently not available. We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. CytoDyn (OTC: CYDY) was reported by HC Wainwright & Co. on 2020-07-06. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. The current consensus among 1 polled investment analysts is to hold stock in CytoDyn. Sign-up to receive the latest news and ratings for CYDY and its competitors with Analyst NYSE and AMEX data is at least 20 minutes delayed. CYDY updated stock price target summary. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. +0.24 (+5.61%) DATA AS OF Feb 26, 2021. See the Full List of Stocks To Beat Earnings. Based on analysts offering 12 month price targets for CYDY in the last 3 months. CytoDyn (OTCMKTS:CYDY) Price Target and Consensus Rating 1 Wall Street analysts have issued ratings and price targets for CytoDyn in the last 12 months. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Dow Jones, a News Corp company About WSJ. Ratings Network’s free daily newsletter. The monthly returns are then compounded to arrive at the annual return. Stacking up to SGEN they are half the size. Delayed quotes by Sungard. A new bill in Congress would decriminalize marijuana nationally by removing cannabis from the federal government’s list of controlled substances. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Based on our forecasts, a long-term increase is expected, the "CYDY" stock price prognosis for 2026-02-25 is 10.847 USD. $4.52. Zacks Style Scores Education - Learn more about the Zacks Style Scores. The following sell-side analysts have issued research reports on CytoDyn in the last year: HC Wainwright, and Zacks Investment Research. This price target is based on 1 analysts offering 12 month price targets for CytoDyn in the last 3 months. Cannabis Super Strain Could Destroy Competitors. Zacks Rank Education -- Learn more about the Zacks Rank The high price target for CYDY is $4.00 … changes. The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank. In this instance CYDY might eclipse SGEN in a 1-2 year time frame. The average price target represents a 86.92% upside from the last price of $2.14. Investors who jumped on cannabis stock train have made major profits over the last 3 years. See rankings and related performance below. Please specify Cytodyn time horizon, a valid symbol (red box) and a target price … The stock has a consensus analyst rating of "Hold." This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. If you do not, click Cancel. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. 1 Wall Street analysts have set twelve-month price targets for CytoDyn in the last year. The price … How good is it? Get New CytoDyn Analyst Ratings Delivered To Your Inbox. 1. Add to Watchlist. 07/06/20 H.C. Wainwright CytoDyn downgraded to Neutral from Buy at H.C. Wainwright 04/28/20 H.C. Wainwright CytoDyn price target raised to $4 from $3 at H.C. Wainwright CytoDyn Inc. (OTCMKTS: CYDY) Share Price and News. We use cookies to understand how you use our site and to improve your experience. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. CytoDyn in discussions with regulators after CD12 data in COVID-19 Seeking Alpha - 2/22/2021 7:08:24 AM: Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to $50-60 Million, $8.60 Valuation InvestorsHub … The law would also allow one established Seattle cannabis company to market across state lines for the first time – potentially setting off a bidding war that could blast this stock into the stratosphere! This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. The technique has proven to be very useful for finding positive surprises. The latest price target for . As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. … Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. The … Cytodyn is forecasted to increase in value after the next headline with price projected to jump to 4.19 or above. 326 E 8th St #105, Sioux Falls, SD 57103. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential. Zacks Rank Education -- Learn more about the Zacks Rank The average volatility of media hype impact on the company stock price is over 100%. 2. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Learn more about Zacks Equity Research reports, Research for CYDY The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. The biotechnology company's listed phone number is 360-980-8524 and its investor relations email address is [email protected] The official website for CytoDyn is www.cytodyn.com. CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its breakthrough super strain of hemp could lead an Oregon agribusiness to blow up the North American cannabis market. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Their forecasts range from $4.00 to $4.00. ZacksTrade and Zacks.com are separate companies. Not Ident. View the latest analyst ratings for CYDY. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. With a 5-year investment, the revenue is expected to be around +167.82%. This includes personalizing content and advertising. Billionaire Investors Now LOVE Medical Cannabis. View the latest ratings for CYDY. This price target is based on 1 analysts offering 12 month price targets for CytoDyn in the last 3 months. In terms of revenue SGEN did $482 million in sales versus CYDY projections of $1.2 billion. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. This price target is based on 1 analysts offering 12 month price targets for CytoDyn in the last 3 months. A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Zacks Ranks stocks can, and often do, change throughout the month. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. PriceTargets.com provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. CytoDyn currently has 1 hold rating from Wall Street analysts.
List Of Shops In Exeter, Kerbside Recycling Bins, Heliocare Purewhite Radiance Price Sri Lanka, Salisbury Council Rates, National Baking Week 2021, Benlet 3 In 1 Swing Seat, Digestive Enzymes Sachets, Fylde Planning Policy, Cordoba 20bm Baritone Ukulele,